293 related articles for article (PubMed ID: 34817209)
1. Broad-Spectrum
Lo MK; Shrivastava-Ranjan P; Chatterjee P; Flint M; Beadle JR; Valiaeva N; Murphy J; Schooley RT; Hostetler KY; Montgomery JM; Spiropoulou CF
Microbiol Spectr; 2021 Dec; 9(3):e0153721. PubMed ID: 34817209
[TBL] [Abstract][Full Text] [Related]
2. Broad-spectrum in vitro antiviral activity of ODBG-P-RVn: an orally-available, lipid-modified monophosphate prodrug of remdesivir parent nucleoside (GS-441524).
Lo MK; Shrivastava-Ranjan P; Chatterjee P; Flint M; Beadle JR; Valiaeva N; Schooley RT; Hostetler KY; Montgomery JM; Spiropoulou C
bioRxiv; 2021 Aug; ():. PubMed ID: 34401879
[TBL] [Abstract][Full Text] [Related]
3. Rethinking Remdesivir: Synthesis, Antiviral Activity, and Pharmacokinetics of Oral Lipid Prodrugs.
Schooley RT; Carlin AF; Beadle JR; Valiaeva N; Zhang XQ; Clark AE; McMillan RE; Leibel SL; McVicar RN; Xie J; Garretson AF; Smith VI; Murphy J; Hostetler KY
Antimicrob Agents Chemother; 2021 Sep; 65(10):e0115521. PubMed ID: 34310217
[TBL] [Abstract][Full Text] [Related]
4. Enhanced broad spectrum in vitro antiviral efficacy of 3-F-4-MeO-Bn, 3-CN, and 4-CN derivatives of lipid remdesivir nucleoside monophosphate prodrugs.
McMillan RE; Lo MK; Zhang XQ; Beadle JR; Valiaeva N; Garretson AF; Clark AE; Freshman JE; Murphy J; Montgomery JM; Spiropoulou CF; Schooley RT; Hostetler KY; Carlin AF
Antiviral Res; 2023 Nov; 219():105718. PubMed ID: 37758067
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic treatment with an oral prodrug of the remdesivir parental nucleoside is protective against SARS-CoV-2 pathogenesis in mice.
Schäfer A; Martinez DR; Won JJ; Meganck RM; Moreira FR; Brown AJ; Gully KL; Zweigart MR; Conrad WS; May SR; Dong S; Kalla R; Chun K; Du Pont V; Babusis D; Tang J; Murakami E; Subramanian R; Barrett KT; Bleier BJ; Bannister R; Feng JY; Bilello JP; Cihlar T; Mackman RL; Montgomery SA; Baric RS; Sheahan TP
Sci Transl Med; 2022 May; 14(643):eabm3410. PubMed ID: 35315683
[TBL] [Abstract][Full Text] [Related]
6. Rethinking Remdesivir: Synthesis, Antiviral Activity and Pharmacokinetics of Oral Lipid Prodrugs.
Schooley RT; Carlin AF; Beadle JR; Valiaeva N; Zhang XQ; Clark AE; McMillan RE; Leibel SL; McVicar RN; Xie J; Garretson AF; Smith VI; Murphy J; Hostetler KY
bioRxiv; 2021 Jun; ():. PubMed ID: 32869033
[TBL] [Abstract][Full Text] [Related]
7. Coronavirus Susceptibility to the Antiviral Remdesivir (GS-5734) Is Mediated by the Viral Polymerase and the Proofreading Exoribonuclease.
Agostini ML; Andres EL; Sims AC; Graham RL; Sheahan TP; Lu X; Smith EC; Case JB; Feng JY; Jordan R; Ray AS; Cihlar T; Siegel D; Mackman RL; Clarke MO; Baric RS; Denison MR
mBio; 2018 Mar; 9(2):. PubMed ID: 29511076
[TBL] [Abstract][Full Text] [Related]
8. Simulation of Remdesivir Pharmacokinetics and Its Drug Interactions.
Deb S; Reeves AA
J Pharm Pharm Sci; 2021; 24():277-291. PubMed ID: 34107241
[TBL] [Abstract][Full Text] [Related]
9. Optimization of the Prodrug Moiety of Remdesivir to Improve Lung Exposure/Selectivity and Enhance Anti-SARS-CoV-2 Activity.
Hu H; Mady Traore MD; Li R; Yuan H; He M; Wen B; Gao W; Jonsson CB; Fitzpatrick EA; Sun D
J Med Chem; 2022 Sep; 65(18):12044-12054. PubMed ID: 36070561
[TBL] [Abstract][Full Text] [Related]
10. A Review on Remdesivir: A Possible Promising Agent for the Treatment of COVID-19.
Hashemian SM; Farhadi T; Velayati AA
Drug Des Devel Ther; 2020; 14():3215-3222. PubMed ID: 32821086
[TBL] [Abstract][Full Text] [Related]
11. Why Remdesivir Failed: Preclinical Assumptions Overestimate the Clinical Efficacy of Remdesivir for COVID-19 and Ebola.
Yan VC; Muller FL
Antimicrob Agents Chemother; 2021 Sep; 65(10):e0111721. PubMed ID: 34252308
[TBL] [Abstract][Full Text] [Related]
12. Remdesivir against COVID-19 and Other Viral Diseases.
Malin JJ; Suárez I; Priesner V; Fätkenheuer G; Rybniker J
Clin Microbiol Rev; 2020 Dec; 34(1):. PubMed ID: 33055231
[TBL] [Abstract][Full Text] [Related]
13. The adenosine analog prodrug ATV006 is orally bioavailable and has preclinical efficacy against parental SARS-CoV-2 and variants.
Cao L; Li Y; Yang S; Li G; Zhou Q; Sun J; Xu T; Yang Y; Liao R; Shi Y; Yang Y; Zhu T; Huang S; Ji Y; Cong F; Luo Y; Zhu Y; Luan H; Zhang H; Chen J; Liu X; Luo R; Liu L; Wang P; Yu Y; Xing F; Ke B; Zheng H; Deng X; Zhang W; Lin C; Shi M; Li CM; Zhang Y; Zhang L; Dai J; Lu H; Zhao J; Zhang X; Guo D
Sci Transl Med; 2022 Sep; 14(661):eabm7621. PubMed ID: 35579533
[TBL] [Abstract][Full Text] [Related]
14. Remdesivir: A beacon of hope from Ebola virus disease to COVID-19.
Nili A; Farbod A; Neishabouri A; Mozafarihashjin M; Tavakolpour S; Mahmoudi H
Rev Med Virol; 2020 Nov; 30(6):1-13. PubMed ID: 33210457
[TBL] [Abstract][Full Text] [Related]
15. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial.
Wang Y; Zhang D; Du G; Du R; Zhao J; Jin Y; Fu S; Gao L; Cheng Z; Lu Q; Hu Y; Luo G; Wang K; Lu Y; Li H; Wang S; Ruan S; Yang C; Mei C; Wang Y; Ding D; Wu F; Tang X; Ye X; Ye Y; Liu B; Yang J; Yin W; Wang A; Fan G; Zhou F; Liu Z; Gu X; Xu J; Shang L; Zhang Y; Cao L; Guo T; Wan Y; Qin H; Jiang Y; Jaki T; Hayden FG; Horby PW; Cao B; Wang C
Lancet; 2020 May; 395(10236):1569-1578. PubMed ID: 32423584
[TBL] [Abstract][Full Text] [Related]
16. Remdesivir and GS-441524 Retain Antiviral Activity against Delta, Omicron, and Other Emergent SARS-CoV-2 Variants.
Pitts J; Li J; Perry JK; Du Pont V; Riola N; Rodriguez L; Lu X; Kurhade C; Xie X; Camus G; Manhas S; Martin R; Shi PY; Cihlar T; Porter DP; Mo H; Maiorova E; Bilello JP
Antimicrob Agents Chemother; 2022 Jun; 66(6):e0022222. PubMed ID: 35532238
[TBL] [Abstract][Full Text] [Related]
17. Oral prodrug of remdesivir parent GS-441524 is efficacious against SARS-CoV-2 in ferrets.
Cox RM; Wolf JD; Lieber CM; Sourimant J; Lin MJ; Babusis D; DuPont V; Chan J; Barrett KT; Lye D; Kalla R; Chun K; Mackman RL; Ye C; Cihlar T; Martinez-Sobrido L; Greninger AL; Bilello JP; Plemper RK
Nat Commun; 2021 Nov; 12(1):6415. PubMed ID: 34741049
[TBL] [Abstract][Full Text] [Related]
18. Remdesivir: From Ebola to COVID-19.
Santoro MG; Carafoli E
Biochem Biophys Res Commun; 2021 Jan; 538():145-150. PubMed ID: 33388129
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetic, Pharmacodynamic, and Drug-Interaction Profile of Remdesivir, a SARS-CoV-2 Replication Inhibitor.
Humeniuk R; Mathias A; Kirby BJ; Lutz JD; Cao H; Osinusi A; Babusis D; Porter D; Wei X; Ling J; Reddy YS; German P
Clin Pharmacokinet; 2021 May; 60(5):569-583. PubMed ID: 33782830
[TBL] [Abstract][Full Text] [Related]
20. Use of remdesivir for patients with Covid-19: a review article.
Azevedo TCP; Azevedo PCP; Silveira Filho RN; Carvalho ARVS; Cezarotti Filho ML; Barbosa FT; Sousa-Rodrigues CF; Matos-Rocha TJ; Ramos FWDS
Rev Assoc Med Bras (1992); 2020 Jun; 66(6):838-841. PubMed ID: 32696862
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
